Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572

Watchlist Manager
Zhejiang CONBA Pharmaceutical Co Ltd Logo
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Watchlist
Price: 4.68 CNY -2.09% Market Closed
Market Cap: 11.7B CNY
Have any thoughts about
Zhejiang CONBA Pharmaceutical Co Ltd?
Write Note

Operating Margin
Zhejiang CONBA Pharmaceutical Co Ltd

9%
Current
12%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
9%
=
Operating Profit
580.3m
/
Revenue
6.5B

Operating Margin Across Competitors

Country CN
Market Cap 11.8B CNY
Operating Margin
9%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 741.7B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.8T DKK
Operating Margin
44%
Country US
Market Cap 346.4B USD
Operating Margin
28%
Country US
Market Cap 250B USD
Operating Margin
34%
Country CH
Market Cap 199.8B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.7B CHF
Operating Margin
31%
Country US
Market Cap 148.7B USD
Operating Margin
22%
No Stocks Found

Zhejiang CONBA Pharmaceutical Co Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Zhejiang CONBA Pharmaceutical Co., Ltd. stands as a prominent figure in the vast landscape of China's pharmaceutical industry. This enterprise, established in the economically vibrant province of Zhejiang, has carved its niche through rigorous adherence to research-driven innovation and quality assurance. While the pharmaceutical realm is competitive and challenging, CONBA has made strategic inroads by focusing on both modern medicine and traditional Chinese medicine (TCM). This dual approach has allowed the company to tap into a rich tapestry of healthcare solutions, catering to diverse consumer needs. By leveraging a robust research and development framework, CONBA continues to enhance its portfolio, offering a wide array of medicinal products including prescription drugs, over-the-counter medications, and healthcare supplements. Financially, Zhejiang CONBA thrives through a multifaceted business model. The company's revenue streams are bolstered by its strong domestic market presence alongside its expanding international footprint. It strategically combines manufacturing prowess with an extensive distribution network, ensuring that its products are readily accessible. Moreover, CONBA's commitment to quality and compliance with international regulatory standards has fostered trust and reinforced its brand reputation both within and outside of China. As it continues to evolve, CONBA remains dedicated to harnessing advancements in biotechnology and pharmacology, aiming to sustain profitability while contributing to the global healthcare dialogue.

Intrinsic Value
8.12 CNY
Undervaluation 42%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
9%
=
Operating Profit
580.3m
/
Revenue
6.5B
What is the Operating Margin of Zhejiang CONBA Pharmaceutical Co Ltd?

Based on Zhejiang CONBA Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of 9%.